TECPORT VISION, INC
ORLANDO, FLORIDA

Mission: To become the , trusted, non-invasive, FDA approved medical device company for the treatment of migraine headaches, by providing patented, high quality, affordable products to migraine sufferers in partnership with the health care system. Company History Tecport Vision is an Orlando, FL based technology company formed to address neurological medical conditions through the application of optical devices. Tecport Vision is wholly owned by Tecport Optics. The foundation for TecportVision resulted from 15 years of R&D and advancements in thin film filter technology at Tecport Optics. Having developed proprietary technologies, Tecport Optics has been a leader in optical solutions in the Defense and Electronics industries. Some of the key products include: Tecport developed the new High-Density Plasma Source. This breakthrough provides the capability to deliver the highest quality performance coatings at a consistent rate. EU has twice awarded Tecport the program to provide technical modernization in small and medium sized enterprises in Bulgaria. Tecport Vision Inc. was created to develop, manufacture, and distribute optical solutions to migraine headaches and other medical conditions. The migraine lens will be marketed under the brand “LEVO Lens”. This business plan addresses the commercialization of a medical device for the prevention/treatment of migraines. Current research is underway utilizing optical solutions to other neurological disorders including certain forms of epilepsy and management of the circadian cycle (resulting in sleep disorders). In addition, certain wavelength exposures may be contributing to the development of certain eye diseases. All of these medical conditions are anticipated to provide future product offerings from TecportVision. may spread from the area of injection to other areas of the body, causing symptoms similar to those of botulism. These symptoms can include swallowing and breathing problems. The FDA says that it knows of no confirmed cases of the spread of the toxic effects when Botox has been used at the recommended doses to treat chronic migraines, severe underarm sweating, or conditions such as blepharospasm (involuntary muscle spasms of the eyelid) The drug can also cause muscle weakness, double vision, blurred vision, drooping eyelids, loss of bladder control and hoarseness, according to the manufacturer – Allergen disclosure statement. The FDA further states that Botox does not appear to be useful in treating or preventing less frequent migraines that occur 14 days or less per month or other forms of headaches. Preliminary test results conducted in Clinical Trials by the University of Utah Moran Eye Center indicated that the TecportVision “LEVO” lens provided a minimum of a 14% reduction in their HIT-6 score (Headache Impact Test -6 or an average 20 % reduction for their patience’s, while by comparing to Botox who had an approximant 10 % reduction. Mission: To become the , trusted, non-invasive, FDA approved medical device company for the treatment of migraine headaches, by providing patented, high quality, affordable products to migraine sufferers in partnership with the health care system. Company History Tecport Vision is an Orlando, FL based technology company formed to address neurological medical conditions through the application of optical devices. Tecport Vision is wholly owned by Tecport Optics. The foundation for TecportVision resulted from 15 years of R&D and advancements in thin film filter technology at Tecport Optics. Having developed proprietary technologies, Tecport Optics has been a leader in optical solutions in the Defense and Electronics industries. Some of the key products include: Tecport developed the new High-Density Plasma Source. This breakthrough provides the capability to deliver the highest quality performance coatings at a consistent rate. EU has twice awarded Tecport the program to provide technical modernization in small and medium sized enterprises in Bulgaria. Tecport Vision Inc. was created to develop, manufacture, and distribute optical solutions to migraine headaches and other medical conditions. The migraine lens will be marketed under the brand “LEVO Lens”. This business plan addresses the commercialization of a medical device for the prevention/treatment of migraines. Current research is underway utilizing optical solutions to other neurological disorders including certain forms of epilepsy and management of the circadian cycle (resulting in sleep disorders). In addition, certain wavelength exposures may be contributing to the development of certain eye diseases. All of these medical conditions are anticipated to provide future product offerings from TecportVision. may spread from the area of injection to other areas of the body, causing symptoms similar to those of botulism. These symptoms can include swallowing and breathing problems. The FDA says that it knows of no confirmed cases of the spread of the toxic effects when Botox has been used at the recommended doses to treat chronic migraines, severe underarm sweating, or conditions such as blepharospasm (involuntary muscle spasms of the eyelid) The drug can also cause muscle weakness, double vision, blurred vision, drooping eyelids, loss of bladder control and hoarseness, according to the manufacturer – Allergen disclosure statement. The FDA further states that Botox does not appear to be useful in treating or preventing less frequent migraines that occur 14 days or less per month or other forms of headaches. Preliminary test results conducted in Clinical Trials by the University of Utah Moran Eye Center indicated that the TecportVision “LEVO” lens provided a minimum of a 14% reduction in their HIT-6 score (Headache Impact Test -6 or an average 20 % reduction for their patience’s, while by comparing to Botox who had an approximant 10 % reduction. were assigned in perpetuity from the Universities. This development led to the creation of a new corporation called TecportVision Inc. The company will develop and deliver medical solutions to neurological issues, utilizing optical technology. TecportVision’s LEVO lens will be offered for the prevention/treatment of migraine headaches.